Mostrar el registro sencillo del ítem
Activation of general control nonderepressible 2 kinase protects human glomerular endothelial cells from harmful high-glucose-induced molecular pathways
| dc.creator | Eleftheriadis T., Tsogka K., Pissas G., Antoniadi G., Liakopoulos V., Stefanidis I. | en |
| dc.date.accessioned | 2023-01-31T07:37:23Z | |
| dc.date.available | 2023-01-31T07:37:23Z | |
| dc.date.issued | 2016 | |
| dc.identifier | 10.1007/s11255-016-1377-x | |
| dc.identifier.issn | 03011623 | |
| dc.identifier.uri | http://hdl.handle.net/11615/71374 | |
| dc.description.abstract | Purpose: Considering the referred beneficial effects of protein restriction on diabetic nephropathy (DN) and the role of renal endothelium in its pathogenesis, we evaluated the effect of general control nonderepressible 2 (GCN2) kinase activation, a sensor of amino acid deprivation, on known detrimental molecular pathways in primary human glomerular endothelial cells (GEnC). Methods: GEnC were cultured under normal or high-glucose conditions in the presence or not of the GCN2 kinase activator, tryptophanol. Glucose transporter 1 (GLUT1) expression was assessed by western blotting and reactive oxygen species (ROS) using a fluorogenic probe. Activities of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and protein kinase C (PKC) were assessed by commercial activity assays, sorbitol colorimetrically, methylglyoxal by ELISA and O-linked β-N-acetyl glucosamine (O-GlcNAc)-modified proteins by western blotting. Results: High glucose induced GLUT1 expression, increased ROS and inhibited GAPDH. Also it increased the polyol pathway product sorbitol, PKC activity, the level of the O-GlcNAc-modified proteins that produced by the hexosamine pathway and the advanced glycation endproducts’ precursor methylglyoxal. Co-treatment of GEnC with tryptophanol restored the above high-glucose-induced alterations. Conclusions: Activation of GCN2 kinase protects GEnC from high-glucose-induced harmful molecular pathways. By inhibiting concurrently many pathways involved in DN pathogenesis, GCN2 kinase may serve as a pharmaceutical target for the treatment of DN. © 2016, Springer Science+Business Media Dordrecht. | en |
| dc.language.iso | en | en |
| dc.source | International Urology and Nephrology | en |
| dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84980039405&doi=10.1007%2fs11255-016-1377-x&partnerID=40&md5=ca444f2c28f9b60d3085f231f2dc34ed | |
| dc.subject | advanced glycation end product | en |
| dc.subject | enzyme activator | en |
| dc.subject | general control nonderepressible 2 kinase | en |
| dc.subject | glucose | en |
| dc.subject | glucose transporter 1 | en |
| dc.subject | glyceraldehyde 3 phosphate dehydrogenase | en |
| dc.subject | hexosamine | en |
| dc.subject | methylglyoxal | en |
| dc.subject | n acetylglucosamine | en |
| dc.subject | phosphotransferase | en |
| dc.subject | polyol | en |
| dc.subject | protein derivative | en |
| dc.subject | protein kinase C | en |
| dc.subject | reactive oxygen metabolite | en |
| dc.subject | sorbitol | en |
| dc.subject | tryptophanol | en |
| dc.subject | unclassified drug | en |
| dc.subject | glucose blood level | en |
| dc.subject | glucose transporter 1 | en |
| dc.subject | glyceraldehyde 3 phosphate dehydrogenase | en |
| dc.subject | glyceraldehyde 3-phosphate dehydrogenase (304-313) | en |
| dc.subject | peptide fragment | en |
| dc.subject | protein kinase C | en |
| dc.subject | tryptophan | en |
| dc.subject | Article | en |
| dc.subject | colorimetry | en |
| dc.subject | controlled study | en |
| dc.subject | endothelium cell | en |
| dc.subject | enzyme activation | en |
| dc.subject | enzyme linked immunosorbent assay | en |
| dc.subject | glomerular endothelial cell | en |
| dc.subject | glomerulus epithelium cell | en |
| dc.subject | human | en |
| dc.subject | human cell | en |
| dc.subject | protein expression | en |
| dc.subject | Western blotting | en |
| dc.subject | analogs and derivatives | en |
| dc.subject | cell culture | en |
| dc.subject | Diabetic Nephropathies | en |
| dc.subject | drug effects | en |
| dc.subject | glucose blood level | en |
| dc.subject | metabolism | en |
| dc.subject | pathology | en |
| dc.subject | protection | en |
| dc.subject | urothelium | en |
| dc.subject | Blood Glucose | en |
| dc.subject | Cells, Cultured | en |
| dc.subject | Diabetic Nephropathies | en |
| dc.subject | Glucose Transporter Type 1 | en |
| dc.subject | Glyceraldehyde-3-Phosphate Dehydrogenases | en |
| dc.subject | Humans | en |
| dc.subject | Peptide Fragments | en |
| dc.subject | Protective Factors | en |
| dc.subject | Protein Kinase C | en |
| dc.subject | Tryptophan | en |
| dc.subject | Urothelium | en |
| dc.subject | Springer Netherlands | en |
| dc.title | Activation of general control nonderepressible 2 kinase protects human glomerular endothelial cells from harmful high-glucose-induced molecular pathways | en |
| dc.type | journalArticle | en |
Ficheros en el ítem
| Ficheros | Tamaño | Formato | Ver |
|---|---|---|---|
|
No hay ficheros asociados a este ítem. |
|||